Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1955 1
1957 1
1972 3
1973 1
1974 3
1975 40
1976 69
1977 55
1978 84
1979 59
1980 69
1981 75
1982 93
1983 82
1984 95
1985 74
1986 104
1987 91
1988 94
1989 91
1990 93
1991 85
1992 117
1993 112
1994 106
1995 101
1996 122
1997 123
1998 100
1999 107
2000 135
2001 126
2002 166
2003 184
2004 205
2005 231
2006 278
2007 298
2008 317
2009 397
2010 455
2011 508
2012 580
2013 567
2014 603
2015 612
2016 576
2017 594
2018 612
2019 615
2020 639
2021 625
2022 597
2023 587
2024 561
2025 607
2026 242

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,721 results

Results by year

Filters applied: . Clear all
Page 1
Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
Mulder NH, van der Graaf WT, Willemse PH, Koops HS, de Vries EG, Sleijfer DT. Mulder NH, et al. Br J Cancer. 1994 Oct;70(4):681-3. doi: 10.1038/bjc.1994.372. Br J Cancer. 1994. PMID: 7522510 Free PMC article. Clinical Trial.
Combinations of dacarbazine (DTIC) and other cytotoxic agents or alpha-interferon were given to 136 patients in five different regimens. ...Although response rates vary among the various regimens described in the literature, the complete response rates are quite sim …
Combinations of dacarbazine (DTIC) and other cytotoxic agents or alpha-interferon were given to 136 patients in five different …
Pharmacokinetics of dacarbazine (DTIC) in pregnancy.
Kantrowitz-Gordon I, Hays K, Kayode O, Kumar AR, Kaplan HG, Reid JM, Safgren SL, Ames MM, Easterling TR, Hebert MF. Kantrowitz-Gordon I, et al. Cancer Chemother Pharmacol. 2018 Mar;81(3):455-460. doi: 10.1007/s00280-017-3511-6. Epub 2018 Jan 5. Cancer Chemother Pharmacol. 2018. PMID: 29305638 Free PMC article.
PURPOSE: The purpose of this report is to describe, for the first time, the pharmacokinetics of dacarbazine (DTIC) and its metabolites [5-[3-methyl-triazen-1-yl]-imidazole-4-carboxamide (MTIC), 5-[3-hydroxymethyl-3-methyl-triazen-1-yl]-imidazole-4-carboxamide (HMMTI …
PURPOSE: The purpose of this report is to describe, for the first time, the pharmacokinetics of dacarbazine (DTIC) and its met …
Biochemotherapy for melanoma.
Philip PA, Flaherty LE. Philip PA, et al. Curr Oncol Rep. 2000 Jul;2(4):314-21. doi: 10.1007/s11912-000-0024-x. Curr Oncol Rep. 2000. PMID: 11122859 Review.
Systemic therapy for advanced melanoma includes chemotherapy, either with dacarbazine (DTIC) alone or a multiagent combination chemotherapy, and biologic therapy with recombinant interferon-alpha and/or interleukin-2. ...
Systemic therapy for advanced melanoma includes chemotherapy, either with dacarbazine (DTIC) alone or a multiagent combination …
Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
Huncharek M, Caubet JF, McGarry R. Huncharek M, et al. Melanoma Res. 2001 Feb;11(1):75-81. doi: 10.1097/00008390-200102000-00009. Melanoma Res. 2001. PMID: 11254118 Clinical Trial.
Non-DTIC-containing treatment programmes showed no advantage over DTIC in terms of tumour response rate (OR = 0.77, 95% CI 0.45-1.32). The combination of DTIC and interferon-alpha appears more active than standard single-agent DTIC in metastatic melano …
Non-DTIC-containing treatment programmes showed no advantage over DTIC in terms of tumour response rate (OR = 0.77, 95% CI 0.4 …
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.
Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB, Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C, Berger T, Kamarashev J, Burg G, Jonuleit H, Tüttenberg A, Becker JC, Keikavoussi P, Kämpgen E, Schuler G; DC study group of the DeCOG. Schadendorf D, et al. Ann Oncol. 2006 Apr;17(4):563-70. doi: 10.1093/annonc/mdj138. Epub 2006 Jan 17. Ann Oncol. 2006. PMID: 16418308 Free article. Clinical Trial.
BACKGROUND: This randomized phase III trial was designed to demonstrate the superiority of autologous peptide-loaded dendritic cell (DC) vaccination over standard dacarbazine (DTIC) chemotherapy in stage IV melanoma patients. PATIENTS AND METHODS: DTIC 850 mg …
BACKGROUND: This randomized phase III trial was designed to demonstrate the superiority of autologous peptide-loaded dendritic cell (DC) vac …
Temozolomide for Treating Malignant Melanoma.
Li RH, Hou XY, Yang CS, Liu WL, Tang JQ, Liu YQ, Jiang G. Li RH, et al. J Coll Physicians Surg Pak. 2015 Sep;25(9):680-8. J Coll Physicians Surg Pak. 2015. PMID: 26374366 Review.
The authors hereby, evaluated the use of temozolomide (TMZ) for treating metastatic melanoma compared to dacarbazine (DTIC), the effectiveness of TMZ for treating brain metastases, as well as TMZ resistance and how the efficacy of TMZ in malignant melanoma can be in …
The authors hereby, evaluated the use of temozolomide (TMZ) for treating metastatic melanoma compared to dacarbazine (DTIC), t …
Dacarbazine (DTIC) in malignant melanoma: reduced toxicity with protection from light.
Koriech OM, Shükla VS. Koriech OM, et al. Clin Radiol. 1981 Jan;32(1):53-5. doi: 10.1016/s0009-9260(81)80251-6. Clin Radiol. 1981. PMID: 7214822
Dacarbazine (dimethyl triazeno imidazole carboxamide, DTIC, NSC-45388), is the most effective oncolytic agent in the treatment of advanced malignant melanoma, but its side effects are considerable. ...Fifteen patients with metastatic malignant melanoma were treated …
Dacarbazine (dimethyl triazeno imidazole carboxamide, DTIC, NSC-45388), is the most effective oncolytic agent in the treatment …
Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma.
Young AM, Marsden J, Goodman A, Burton A, Dunn JA. Young AM, et al. Clin Oncol (R Coll Radiol). 2001;13(6):458-65. doi: 10.1053/clon.2001.9314. Clin Oncol (R Coll Radiol). 2001. PMID: 11824887 Clinical Trial.
Dacarbazine (DTIC) has been the mainstay of chemotherapy for metastatic melanoma for over two decades, but only 15%-20% of patients respond and benefit is usually transient. ...The 6-month survival of those patients randomized to DTIC alone was 58% compared w …
Dacarbazine (DTIC) has been the mainstay of chemotherapy for metastatic melanoma for over two decades, but only 15%-20% of pat …
Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules.
Breithaupt H, Dammann A, Aigner K. Breithaupt H, et al. Cancer Chemother Pharmacol. 1982;9(2):103-9. doi: 10.1007/BF00265388. Cancer Chemother Pharmacol. 1982. PMID: 7172404
The pharmacokinetics of dacarbazine (DTIC) and its main metabolite 5-aminoimidazole-4-carboxamide (AIC) have been studied in eight patients with malignant melanoma or sarcoma receiving 2.65--6.85 mg DTIC/kg body weight by intravenous bolus injection or by con …
The pharmacokinetics of dacarbazine (DTIC) and its main metabolite 5-aminoimidazole-4-carboxamide (AIC) have been studied in e …
12,721 results
You have reached the last available page of results. Please see the User Guide for more information.